Supplier
Zeeland Community Hospital
Zeeland Community Hospital was paid $10.12M by Medicaid between Jan 2018 and Dec 2024, across 188 billing codes. Its largest line is 99284, emergency room visit (serious) — 23% of everything it billed.
33Billing provider infoZEELAND COMMUNITY HOSPITAL
ZEELAND, MI 49464
ZEELAND, MI 49464
33aNPI1275536344assigned 05/23/2005
33bProvider typeInstitutional Pharmacy
28Total paid$10.12M
24GClaims326,299
24DCodes billed188
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COX, MATTHEW controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,588 | $636K | |
| 2019 | 17,946 | $524K | |
| 2020 | 34,108 | $1.06M | |
| 2021 | 68,114 | $2.08M | |
| 2022 | 64,303 | $2.05M | |
| 2023 | 66,313 | $2.03M | |
| 2024incomplete | 53,927 | $1.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 11,411 | 10,762 | $2.31M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 4,412 | 4,214 | $1.45M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 10,519 | 10,082 | $1.35M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 8.6% | 8,798 | 7,928 | $871K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 5.6% | 8,488 | 8,209 | $567K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 2,885 | 2,804 | $458K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 5,402 | 5,263 | $401K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.2% | 2,184 | 2,157 | $226K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 6,405 | 5,400 | $181K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 3,683 | 3,591 | $153K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 7,133 | 6,046 | $146K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 1,438 | 1,098 | $136K |
176 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 1,173 | $123K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 4,105 | $116K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.1% | 5,641 | $108K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,485 | $81K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,117 | $70K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,516 | $64K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 114 | $58K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,912 | $57K |
| 82947 | <1% | 2,493 | $55K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,134 | $53K |
| 93975 | <1% | 430 | $53K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 131 | $50K |
| 80061 | Lipid panel | <1% | 2,322 | $47K |
| 76830 | Ultrasound, transvaginal | <1% | 776 | $45K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,064 | $45K |
| 86900 | <1% | 1,157 | $41K | |
| 71045 | Radiologic examination, chest; single view | <1% | 940 | $38K |
| 36415 | Collection of venous blood by venipuncture | <1% | 18,632 | $38K |
| 80050 | General health panel | <1% | 1,329 | $37K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 306 | $35K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,373 | $34K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 459 | $34K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,358 | $34K |
| C9399 | Unclassified drugs or biologicals | <1% | 376 | $28K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 1,047 | $26K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 441 | $22K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 200 | $21K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,498 | $20K |
| 80053 | Comprehensive metabolic panel | <1% | 16,162 | $20K |
| 92526 | <1% | 471 | $19K | |
| 74230 | <1% | 177 | $17K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 504 | $17K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,494 | $15K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 529 | $14K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 886 | $13K |
| G0378 | Hospital observation service, per hour | <1% | 188 | $12K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 168 | $12K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 741 | $11K |
| 0012A | <1% | 338 | $11K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,183 | $11K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 63 | $10K |
| 76642 | <1% | 237 | $10K | |
| 92611 | <1% | 188 | $9K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 885 | $9K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 744 | $9K |
| 84702 | <1% | 1,600 | $8K | |
| 73610 | <1% | 479 | $8K | |
| 82728 | <1% | 1,240 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,803 | $8K |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 718 | $8K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 152 | $8K |
| 85027 | <1% | 3,876 | $7K | |
| 0011A | <1% | 325 | $7K | |
| 73630 | <1% | 475 | $7K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 38 | $6K |
| 87653 | <1% | 351 | $6K | |
| 86780 | <1% | 821 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 674 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,734 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,398 | $6K |
| 87081 | <1% | 2,335 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 260 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,406 | $5K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,754 | $5K |
| 83655 | <1% | 664 | $5K | |
| 83550 | <1% | 1,042 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,104 | $4K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 32 | $4K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 317 | $4K |
| 96376 | <1% | 1,626 | $4K | |
| 87077 | <1% | 1,457 | $3K | |
| 83540 | <1% | 1,053 | $3K | |
| 73110 | <1% | 190 | $3K | |
| 82607 | <1% | 516 | $3K | |
| 93971 | <1% | 54 | $3K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 15 | $3K |
| 73130 | <1% | 161 | $2K | |
| 87186 | <1% | 926 | $2K | |
| 76801 | <1% | 41 | $2K | |
| 87205 | <1% | 1,604 | $2K | |
| 83735 | <1% | 3,122 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 67 | $2K |
| 72100 | <1% | 71 | $2K | |
| 97162 | <1% | 38 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 25 | $2K |
| 81001 | <1% | 10,327 | $2K | |
| 84439 | <1% | 391 | $1K | |
| 73562 | <1% | 77 | $1K | |
| 73030 | <1% | 95 | $1K | |
| 82570 | <1% | 745 | $1K | |
| 83880 | <1% | 493 | $1K | |
| 85610 | <1% | 1,007 | $1K | |
| 86140 | <1% | 751 | $926.71 | |
| 0031A | <1% | 24 | $908.40 | |
| 87340 | <1% | 486 | $865.39 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 84 | $848.23 |
| 82746 | <1% | 118 | $832.73 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 126 | $778.50 |
| 87070 | <1% | 249 | $752.21 | |
| 0001A | <1% | 20 | $742.95 | |
| 86850 | <1% | 999 | $734.51 | |
| 83690 | <1% | 4,852 | $725.97 | |
| 97802 | <1% | 12 | $717.40 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 14 | $711.09 |
| 71250 | <1% | 13 | $696.14 | |
| 84425 | <1% | 64 | $693.57 | |
| 85652 | <1% | 716 | $636.29 | |
| 74018 | <1% | 24 | $632.24 | |
| 81025 | <1% | 6,554 | $607.02 | |
| 84100 | <1% | 491 | $561.72 | |
| 0002A | <1% | 14 | $529.90 | |
| 96415 | <1% | 14 | $511.11 | |
| 87808 | <1% | 309 | $364.32 | |
| 82565 | <1% | 2,806 | $355.44 | |
| 87147 | <1% | 208 | $325.74 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 14 | $212.76 |
| 85007 | <1% | 260 | $210.50 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 57 | $202.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 907 | $185.20 |
| 84156 | <1% | 188 | $178.40 | |
| 85730 | <1% | 198 | $166.64 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 75 | $151.13 |
| 85379 | <1% | 342 | $104.30 | |
| 82950 | <1% | 39 | $104.12 | |
| 87807 | <1% | 86 | $101.14 | |
| 84484 | <1% | 2,891 | $64.73 | |
| 81000 | <1% | 309 | $59.44 | |
| 80076 | <1% | 14 | $53.64 | |
| 82247 | <1% | 16 | $44.85 | |
| 80069 | <1% | 15 | $43.56 | |
| 83605 | <1% | 763 | $40.85 | |
| 82043 | <1% | 12 | $35.68 | |
| 86762 | <1% | 91 | $33.50 | |
| 87040 | <1% | 20 | $24.34 | |
| 82248 | <1% | 14 | $23.52 | |
| 86308 | <1% | 15 | $20.93 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,372 | $1.40 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 6,431 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,629 | $0.00 |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 151 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 991 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 4,236 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,514 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 578 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 102 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,577 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 609 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 2,843 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 193 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 378 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 94 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 264 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 305 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 121 | $0.00 |
| A9270 | Non-covered item or service | 0% | 76 | $0.00 |
| 91301 | 0% | 665 | $0.00 | |
| 82077 | 0% | 41 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 28 | $0.00 |
| 91303 | 0% | 23 | $0.00 | |
| 87503 | 0% | 13 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 17 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 4,086 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 2,229 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 1,429 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 57 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 6,947 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 4,459 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 615 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 9,693 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 6,108 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 624 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 57 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 360 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 117 | $0.00 |
| 91300 | 0% | 31 | $0.00 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOX, MATTHEW (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.